Concert Pharmaceuticals, Inc. IPO Research Information

Concert Pharmaceuticals, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Concert Pharmaceuticals, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Concert Pharmaceuticals, Inc.	CNCE - NASDAQ	$12.00-$14.00	$14.00	$15.75	6 million	2/13/2014
Underwriter(s): UBS Investment Bank, Wells Fargo Securities
Co-Manager(s): JMP Securities, Roth Capital Partners
Industry: Health Care
Filing(s): Filed 2014-01-13

Concert Pharmaceuticals, Inc. Quote & Chart - Click for current quote - CNCE

About Concert Pharmaceuticals, Inc. (adapted from Concert Pharmaceuticals, Inc. prospectus):
They are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs.

This description is adapted from Concert CNCE prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as Concert CNCE "CNCE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.